Arbutus Biopharma (ABUS) Income towards Parent Company: 2009-2024
Historic Income towards Parent Company for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to -$69.9 million.
- Arbutus Biopharma's Income towards Parent Company rose 60.81% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 44.89%. This contributed to the annual value of -$69.9 million for FY2024, which is 4.02% up from last year.
- As of FY2024, Arbutus Biopharma's Income towards Parent Company stood at -$69.9 million, which was up 4.02% from -$72.8 million recorded in FY2023.
- Arbutus Biopharma's Income towards Parent Company's 5-year high stood at -$63.7 million during FY2020, with a 5-year trough of -$76.2 million in FY2021.
- Moreover, its 3-year median value for Income towards Parent Company was -$69.9 million (2024), whereas its average is -$70.7 million.
- Per our database at Business Quant, Arbutus Biopharma's Income towards Parent Company spiked by 58.53% in 2020 and then dropped by 19.61% in 2021.
- Yearly analysis of 5 years shows Arbutus Biopharma's Income towards Parent Company stood at -$63.7 million in 2020, then declined by 19.61% to -$76.2 million in 2021, then rose by 8.91% to -$69.5 million in 2022, then dropped by 4.89% to -$72.8 million in 2023, then grew by 4.02% to -$69.9 million in 2024.